Thalys(SH:603716) Sou Hu Cai Jing·2025-08-17 16:38Core Viewpoint - The company, Saily Medical, is actively developing digital therapies in the field of brain science, particularly focusing on mental health management through innovative software solutions and strategic collaborations with leading institutions and technology partners [1]. Group 1: Company Developments - As of August 15, 2025, Saily Medical's stock closed at 28.41 yuan, down 3.69%, with a turnover rate of 18.76% and a trading volume of 358,300 hands, resulting in a transaction amount of 1.017 billion yuan [1]. - The company has established a digital management software named "Haisi Lingxi" aimed at assisting in the management of major mental illnesses such as depression and bipolar disorder, leveraging AI and internet technologies [1]. - In April 2025, Saily Medical launched an AI diagnostic technology research center (TAIDxLab) in Shanghai, focusing on rapid molecular diagnostics for infections and critical conditions, as well as digital therapies for brain science [1]. Group 2: Strategic Collaborations - Saily Medical has partnered with Huawei Technologies and a key national laboratory to explore the application of brain science models in psychiatry, aiming to transition the industry from experience-driven to data-driven approaches [1]. - The collaboration with Zhejiang University First Affiliated Hospital's Mental Health Center is part of a national key project for the prevention and treatment of common mental disorders, which commenced in April 2024 [1]. - The partnership aims to build a closed-loop system for secure and reliable medical data processing, integrating resources from medical institutions, pharmaceutical companies, and regulatory bodies [1]. Group 3: Market Activity - On August 15, 2025, the net outflow of main funds from Saily Medical was 136 million yuan, accounting for 13.35% of the total transaction amount [2][3]. - Retail investors showed a net inflow of 147 million yuan, representing 14.49% of the total transaction amount, indicating strong interest from individual investors despite the outflow from institutional funds [3].